TetraPhase secures $15 million
This article was originally published in Scrip
Executive Summary
TetraPhase Pharmaceuticalshas raised $15 million to support its synthetic chemistry platform in the second tranche of its $25 million fundraising. The US firm, which was established in 2006, will discover antibiotics to treat drug-resistant infections. TetraPhase's proprietary technology is aimed at finding new classes of antibiotics and drugs by enabling the total synthesis of the product from its basic building blocks. The series A round was funded by Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures and Skyline Ventures.